ICPT Intercept Pharmaceuticals Inc.

-1.05  -1%
Previous Close 87.38
Open 87.69
Price To Book 134.89
Market Cap 2563472315
Shares 29,693,876
Volume 369,520
Short Ratio
Av. Daily Volume 1,271,210

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 enrolment to be completed in 2019.
Ocaliva - Obeticholic acid (OCA) - REVERSE
NASH patients with compensated cirrhosis
Phase 2 primary endpoint met - July 31, 2017. One patient death noted but DSMB noted unlikely to be related to OCA (company unsure).
Obeticholic acid (OCA) - CONTROL
NASH patients taking statins
Approved May 27 2016. Updated U.S. label for Ocaliva anticipated by early 2018
Obeticholic acid (Ocaliva)
Primary biliary cirrhosis (PBC) - POISE
Phase 3 data met one of two co-primary endpoints - February 19, 2019. Additional data presented April 11, 2019.
Ocaliva (Obeticholic acid (OCA)) - REGENERATE
Adult nonalcoholic steatohepatitis (NASH) patients.
Phase 2 data released July 31, 2017 - primary endpoint met. Late breaker at AASLD October 23, 2017.
Obeticholic acid (OCA) AESOP
Primary Sclerosing Cholangitis (PSC)

Latest News

  1. 5 Top Pharmaceutical Stocks to Buy in 2019
  2. 3 Top Healthcare Stocks to Buy in April
  3. Gilead to Collaborate with Novo Nordisk for NASH Treatment
  4. Why Intercept's Success Was a Big Disappointment
  5. Why Intercept Pharmaceuticals, Weight Watchers International, and Canopy Growth Slumped Today
  6. Is Intercept Pharma's Updated Late-Stage NASH Data A Sell-The-News Event?
  7. Intercept Reports Additional Positive Data From NASH Study
  8. The Daily Biotech Pulse: NASH Cheer For Intercept, Gilead Layoffs, BioDelivery Licenses Constipation Drug
  9. Intercept Reports Additional Positive Data from REGENERATE, the First Successful Phase 3 Study in NASH
  10. See what the IHS Markit Score report has to say about Intercept Pharmaceuticals Inc.
  11. The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts
  12. Intercept to Present Results from the First Successful Phase 3 Trial in Patients with Liver Fibrosis Due to NASH at the International Liver Congress™ 2019
  13. Better Buy: Intercept Pharmaceuticals vs. Gilead Sciences
  14. Novartis (NVS) to Acquire Subsidiary of IFM Therapeutics
  15. 3 Top Biotech Stocks to Buy Right Now
  16. 2 Biotechs With Big Dates in April
  17. How Many Insiders Sold Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Shares?
  18. Why Is Intercept (ICPT) Up 12.2% Since Last Earnings Report?
  19. Conatus (CNAT) Declines on Failure of NASH Fibrosis Study